drugset / Trial / NCT04552288

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

NCT04552288

Phase 2 Completed 51 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.

Timeline

Start
2020-09-16
Primary completion
2024-07-19
Completion
2026-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Benralizumab Monoclonal antibody 30 mg Subcutaneous